Abionyx Pharma SA (ABNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million ≈ $-1.99 Million USD) by net assets (€5.41 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abionyx Pharma SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Abionyx Pharma SA for a breakdown of total debt and financial obligations.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silk Logistics Holdings Ltd
AU:SLH
|
0.381x |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
-0.092x |
|
Moens Bank A/S
CO:MNBA
|
N/A |
|
Bank Qnb Indonesia Tbk
JK:BKSW
|
0.027x |
|
Joyce Corporation Ltd
AU:JYC
|
0.524x |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
-1.170x |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
0.000x |
|
G50 Corp Ltd
AU:G50
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Abionyx Pharma SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.485x | -3.88% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
€-3.70 Million ≈ $-4.32 Million |
-0.467x | +0.37% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
€-3.36 Million ≈ $-3.93 Million |
-0.469x | +25.24% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
€-6.69 Million ≈ $-7.82 Million |
-0.627x | -593.63% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
€-599.00K ≈ $-700.29K |
-0.090x | +84.75% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
€-3.95 Million ≈ $-4.62 Million |
-0.593x | +62.11% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
€-6.00 Million ≈ $-7.02 Million |
-1.564x | -52.89% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
€-9.09 Million ≈ $-10.63 Million |
-1.023x | +22.15% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
€-19.20 Million ≈ $-22.44 Million |
-1.314x | -218.16% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
€-13.71 Million ≈ $-16.03 Million |
-0.413x | +99.85% |
| 2014-12-31 | €12.00K ≈ $14.03K |
€-3.30 Million ≈ $-3.86 Million |
-275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
€-14.49 Million ≈ $-16.94 Million |
-2.352x | -- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more